Literature DB >> 7735697

Interaction between methotrexate and indomethacin on a human normal haemopoietic cell line.

S J Hollingsworth1, N P Shankley, E M Anderson, A Bennett.   

Abstract

1. The interaction between methotrexate and indomethacin has been examined, at a physiological folate concentration (20 nM), on a human normal lymphoblast-like cell line (RPMI 1788) in vitro. 2. Indomethacin (1 microgram ml-1) increased the reduction of lymphoblast growth caused by methotrexate (10-80 ng ml-1). 3. Indomethacin (0.1 and 1 microgram ml-1) potentiated the cytotoxicity of methotrexate (20 and 40 ng ml-1) after 4 days in culture. 4. Indomethacin (0.4 micrograms ml-1) reduced the accumulation of tritium in lymphoblasts incubated with [3H]-methotrexate after 30 min; therefore initial drug accumulation was not responsible for the potentiation seen after 4 days. 5. If indomethacin increases the killing of human cancer cells by methotrexate in vivo, with a smaller potentiation on lymphoblasts, this combination may be beneficial in treating human malignancy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7735697      PMCID: PMC1510021          DOI: 10.1111/j.1476-5381.1995.tb17197.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  Cyclic adenosine 3':5'-monophosphate and methotrexate transport in L1210 cells.

Authors:  G B Henderson; E M Zevely; F M Huennekens
Journal:  Cancer Res       Date:  1978-03       Impact factor: 12.701

2.  Chromosomes of 14 hematopoietic cell lines derived from peripheral blood of persons with and without chromosome anomalies.

Authors:  C C Huang; G E Moore
Journal:  J Natl Cancer Inst       Date:  1969-11       Impact factor: 13.506

3.  Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration.

Authors:  N M Ellison; R J Servi
Journal:  Cancer Treat Rep       Date:  1985-03

Review 4.  Anti-rheumatic drug interactions.

Authors:  R O Day; G G Graham; G D Champion; E Lee
Journal:  Clin Rheum Dis       Date:  1984-08

5.  A new method for studying cell growth in suspension, and its use to show that indomethacin enhances cell killing by methotrexate.

Authors:  J D Gaffen; A Bennett; M R Barer
Journal:  J Pharm Pharmacol       Date:  1985-04       Impact factor: 3.765

6.  Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.

Authors:  D D Von Hoff; J S Penta; L J Helman; M Slavik
Journal:  Cancer Treat Rep       Date:  1977-07

7.  Competitive inhibition of methotrexate accumulation in rabbit kidney slices by nonsteroidal anti-inflammatory drugs.

Authors:  D W Nierenberg
Journal:  J Pharmacol Exp Ther       Date:  1983-07       Impact factor: 4.030

8.  Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen.

Authors:  A Thyss; G Milano; J Kubar; M Namer; M Schneider
Journal:  Lancet       Date:  1986-02-01       Impact factor: 79.321

Review 9.  Obligate genetic expression in tumor cells of a fetal membrane property mediating "folate" transport: biological significance and implications for improved therapy of human cancer.

Authors:  F M Sirotnak
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

10.  NG-hydroxy-L-arginine prevents the haemodynamic effects of nitric oxide synthesis inhibition in the anaesthetized rat.

Authors:  C E Walder; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.